IM8N Stock Overview
A biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.50 |
| 52 Week High | US$72.00 |
| 52 Week Low | US$20.00 |
| Beta | 1.11 |
| 11 Month Change | 0% |
| 3 Month Change | 20.18% |
| 1 Year Change | 200.44% |
| 33 Year Change | 178.46% |
| 5 Year Change | 297.56% |
| Change since IPO | 858.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM8N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | -1.0% |
| 1Y | 200.4% | -9.9% | 12.8% |
Return vs Industry: IM8N exceeded the German Biotechs industry which returned -9.9% over the past year.
Return vs Market: IM8N exceeded the German Market which returned 12.8% over the past year.
Price Volatility
| IM8N volatility | |
|---|---|
| IM8N Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IM8N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine IM8N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 912 | Will Lewis | www.insmed.com |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
Insmed Incorporated Fundamentals Summary
| IM8N fundamental statistics | |
|---|---|
| Market cap | €11.12b |
| Earnings (TTM) | -€727.72m |
| Revenue (TTM) | €297.91m |
37.3x
P/S Ratio-15.3x
P/E RatioIs IM8N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM8N income statement (TTM) | |
|---|---|
| Revenue | US$328.61m |
| Cost of Revenue | US$73.57m |
| Gross Profit | US$255.04m |
| Other Expenses | US$1.06b |
| Earnings | -US$802.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.67 |
| Gross Margin | 77.61% |
| Net Profit Margin | -244.27% |
| Debt/Equity Ratio | 3,425.3% |
How did IM8N perform over the long term?
See historical performance and comparison